期刊
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
卷 90, 期 5, 页码 840-845出版社
AMER SOC TROP MED & HYGIENE
DOI: 10.4269/ajtmh.13-0214
关键词
-
资金
- United States Agency for International Development under the Amazon Malaria Initiative
- Pan American Health Organization
- Network for Surveillance of Antimalarial Drug Resistance
- Ministry of Health of Nicaragua
- Atlanta Research and Education Foundation (Decatur, GA)
- Centers for Disease Control and Prevention Emerging Infectious Diseases Fellowship
Chloroquine (CQ) is used as a first-line therapy for the treatment of Plasmodium falciparum malaria in Nicaragua. We investigated the prevalence of molecular markers associated with CQ and sulfadoxine-pyrimethamine (SP) resistance in P. falciparum isolates obtained from the North Atlantic Autonomous Region of Nicaragua. Blood spots for this study were made available from a CO and SP drug efficacy trial conducted in 2005 and also from a surveillance study performed in 2011. Polymorphisms in P. faciparum CQ resistance transporter, dihydrofolate reductase, and dihydropteroate synthase gene loci that are associated with resistance to CQ, pyrimethamine, and sulfadoxine, respectively, were detected by DNA sequencing. In the 2005 dataset, only 2 of 53 isolates had a CO resistance allele (CVIET), 2 of 52 had a pyrimethamine resistance allele, and 1 of 49 had a sulfadoxine resistance allele. In the 2011 dataset, none of 45 isolates analyzed had CO or SP resistance alleles.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据